Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,540 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allogeneic Hematopoietic Cell Transplantation Clear all
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jun 25, 2026, 3:20 PM EDT
Suspended Phase 1 Interventional

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03494569
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Minimal Residual Disease, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Fludarabine, Laboratory Biomarker Analysis, Melphalan, Total Marrow Irradiation
Drug · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

NCT02694770
View directory record Official record
Conditions
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
Interventions
Neihulizumab Treatment, Conventional Treatment
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

NCT00186394
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
Interventions
ablative allogeneic hematopoietic cell transplantation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 61 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 2 Interventional

Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

NCT04117477
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Xylitol, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 25, 2026, 3:20 PM EDT
Withdrawn Phase 2 Interventional

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

NCT06337331
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Venetoclax, Decitabine, Fludarabine, Busulfan, Total Body Irradiation
Drug · Radiation
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Results available

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT01010867
View directory record Official record
Conditions
Hematopoietic Organs; Disorder
Interventions
Lactobacillus plantarum strains 299 and 299v
Drug
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • St. Petersburg, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jun 25, 2026, 3:20 PM EDT
Recruiting Phase 1 Interventional

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

NCT04375631
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions
Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

NCT02841995
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Belumosudil (KD025)
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Duarte, California • Minneapolis, Minnesota • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional

Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma

NCT00003195
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon alfa, busulfan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 1 Interventional

Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT

NCT01274377
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
CMV Specific T Cell donor lymphocyte infusion
Biological
Lead sponsor
Nelson Chao
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Transplant for Hematological Malignancy

NCT00176930
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Interventions
Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation, Busulfan, Equine ATG (ATGAM), CD4+/CD25+ cells
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT01433965
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Lenalidomide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

NCT01410344
View directory record Official record
Conditions
Leukemia, Lymphoma, HIV
Interventions
Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Cyclophosphamide and Total Body Irradiation
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

NCT03032783
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Hematopoietic Stem Cell Transplantation
Radiation · Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadephia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

NCT00048737
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
Zevalin Radioimmunotherapy, Rituximab, Fludarabine, Cyclophosphamide, Allogeneic Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

FT576 in Subjects With Multiple Myeloma

NCT05182073
View directory record Official record
Conditions
Multiple Myeloma, Myeloma
Interventions
FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 25, 2026, 3:20 PM EDT
Not yet recruiting No phase listed Observational

Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)

NCT07381205
View directory record Official record
Conditions
Transplant Associated Microangiopathy TAM, Transplant Complication
Interventions
Not listed
Lead sponsor
Manuel Ricardo Espinoza-Gutarra
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Withdrawn No phase listed Observational

Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)

NCT01569373
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

NCT00185640
View directory record Official record
Conditions
Blood Cancer, Leukemia
Interventions
Cyclosporine, Anti-thymocyte globulin (ATG), Mycophenolate mofetil (MMF), Filgrastim, Total Lymphoid Irradiation (TLI)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 1 Interventional

Lenalidomide After Allo Transplant

NCT01750762
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jun 25, 2026, 3:20 PM EDT
Recruiting Phase 1 Interventional

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

NCT05443425
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions
Cholestyramine, Leflunomide, Steroid Therapy
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jun 25, 2026, 3:20 PM EDT
Not yet recruiting Phase 1 Interventional

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

NCT07302776
View directory record Official record
Conditions
GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Tacrolimus, Early Tacrolimus Taper Strategy
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 25, 2026, 3:20 PM EDT